Medifast (NYSE:MED) Stock: Insider Daniel Chard Sells 9,545 Shares

Medifast Inc (NYSE:MED) Director Daniel Chard sold 9,545 shares of the firm’s stock in a transaction on Monday, September 28th. The stock was sold at an average price of $11.98, for a total value of $114,349.10. Following the transaction, the director owned 140,153 shares in the company, valued at $1,679,032.94. The trade was a 6.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Medifast Stock Performance

NYSE MED traded down $0.09 on Wednesday, reaching $11.53. 138,133 shares of the stock traded hands, compared to its average volume of 113,400. Medifast Inc has a 12 month low of $9.22 and a 12 month high of $14.15. The company has a market cap of $128.85 million, a price-to-earnings ratio of -4.95 and a beta of 0.71. The company has a fifty day moving average price of $11.67 and a 200-day moving average price of $11.34.

Medifast (NYSE:MED) last posted its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.37. The business had revenue of $76.38 million for the quarter, compared to the consensus estimate of $72.70 million. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%.Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. As a group, research analysts anticipate that Medifast Inc will post -1.04 earnings per share for the current fiscal year.

Institutional Trading of Medifast

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Medifast in the 2nd quarter valued at $3,920,000. Bank of America Corp DE purchased a new stake in shares of Medifast during the 2nd quarter worth $924,000. Empowered Funds LLC purchased a new stake in shares of Medifast during the 2nd quarter worth $701,000. Great Lakes Advisors LLC bought a new stake in Medifast during the second quarter valued at about $548,000. Finally, GSA Capital Partners LLP bought a new stake in Medifast during the second quarter valued at about $408,000. Institutional investors own 95.51% of the company’s stock.

Wall Street Analyst Weigh In

MED has been the topic of several recent research reports. Zacks Research cut shares of Medifast from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of Medifast from a “sell (e+)” rating to a “sell (d)” rating in a report on Monday, August 17th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Medifast presently has an average rating of “Reduce” and an average price target of $12.00.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company that provides weight-management and healthy-lifestyle products and programs. Its principal brand is OPTAVIA, which offers structured plans designed to support weight loss, nutrition, and long-term habit development.

The company’s product portfolio includes meal-replacement shakes, bars, snacks, entrees, beverages, supplements, and other packaged “Fuelings.” Medifast also supports customers through independent OPTAVIA Coaches, who provide guidance, accountability, and lifestyle support through the company’s direct-selling model.

Founded in 1980, Medifast serves customers primarily in the United States through its e-commerce and direct-to-consumer channels.